Mechanisms of disease: Mechanisms and clinical implications of cholestasis in sepsis

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 10, 2006, Pages 574-585

  Geier, Andreas ^a   Fickert, Peter ^b   Trauner, Michael ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYTOKINE; HYDROCORTISONE; NITRIC OXIDE; UREIDOPENICILLIN DERIVATIVE; URSODEOXYCHOLIC ACID;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; BILE DUCT; BILE SECRETION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; ENZYME INDUCTION; ERADICATION THERAPY; HUMAN; IMMUNOMODULATION; INFECTION CONTROL; INTRAHEPATIC CHOLESTASIS; LIVER ISCHEMIA; LIVER SUPPORT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SAFETY; SCLEROSING CHOLANGITIS; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; BACTERIAL INFECTIONS; BILE; BILE DUCTS; CHOLESTASIS; CYTOKINES; HUMANS; LIVER; LIVER DISEASES; LIVER TRANSPLANTATION; NITRIC OXIDE; SEPSIS; URSODEOXYCHOLIC ACID;

EID: 33749356605     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0602     Document Type: Review

References (89)

1. Bone RC et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/ Society of Critical Care Medicine. Chest 101: 1644-1655
2. Lolis E and Bucala R (2003) Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat Rev Drug Discov 2: 635-645
3. Dhainaut JF et al. (2001) Hepatic response to sepsis: Interaction between coagulation and inflammatory processes. Crit Care Med 29 (Suppl): S42-S47
4. Trauner M et al. (1999) Inflammation-induced cholestasis. J Gastroenterol Hepatol 14: 946-959
5. Moseley R (1997) Sepsis-associated cholestasis. Gastroenterology 112: 302-306
6. Martin GS et al. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554
7. Whitehead MW et al. (2001) The causes of obvious jaundice in South West Wales: Perceptions versus reality. Gut 48: 409-413
8. Pastores SM et al. (1996) Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Am J Gastroenterol 91: 1697-1710
9. Trauner M et al. (1998) Molecular pathogenesis of cholestasis. N Engl J Med 339: 1217-1227
10. Benninger J et al. (2005) Sclerosing cholangitis following severe trauma: Description of a remarkable disease entity with emphasis on possible pathophysiologic mechanisms. World J Gastroenterol 11: 4199-4205
11. Engler S et al. (2003) Progressive sclerosing cholangitis after septic shock: A new variant of vanishing bile duct disorders. Gut 52: 688-693
12. Trauner M and Boyer JL (2003) Bile salt transporters: Molecular characterization, function, and regulation. Physiol Rev 83: 633-671
13. Seward DJ et al. (2003) Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTα-OSTβ. J Biol Chem 278: 27473-27482
14. Boyer JL et al. (2006) Up-regulation of a basolateral FXR-dependent bile acid efflux transporter, OSTα-OSTβ, in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 290: G1124-G1130
15. Strazzabosco M et al. (2005) Pathophysiology of cholangiopathies. J Clin Gastroenterol 39 (Suppl 2): S90-S102
16. Karpen SJ (2002) Nuclear receptor regulation of hepatic function. J Hepatol 36: 832-850
17. Eloranta JJ and Kullak-Ublick GA (2005) Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 433: 397-412
18. Arrese M and Trauner M (2003) Molecular aspects of bile formation and cholestasis. Trends Mol Med 9: 558-564
19. Trauner M et al. (1999) Molecular regulation of hepatocellular transport systems in cholestasis. J Hepatol 31: 165-178
20. Moseley RH (2004) Sepsis and cholestasis. Clin Liver Dis 8: 83-94
21. Crawford JM (1997) Cellular and molecular biology of the inflamed liver. Curr Opin Gastroenterol 13: 175-185
22. Luster MI et al. (1994) Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology 19: 480-488
23. Sewnath ME et al. (2002) Interleukin-1 receptor type I gene-deficient bile duct-ligated mice are partially protected against endotoxin. Hepatology 35: 149-158
24. Lazaridis KN et al. (2004) The cholangiopathies: Disorders of biliary epithelia. Gastroenterology 127: 1565-1577
25. Fong YM et al. (1990) The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85: 1896-1904
26. Roelofsen H et al. (1995) Impaired hepatocanalicular organic anion transport in endotoxemic rats. Am J Physiol 269: G427-G434
27. Whiting JF et al. (1995) Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology 22: 1273-1278
28. Blaschke TF et al. (1973) Effects of induced fever on sulfobromophthalein kinetics in man. Ann Intern Med 78: 221-226
29. Jones A et al. (1990) Tumour necrosis factor, cholestatic jaundice, and chronic liver disease. Gut 31: 938-939
30. Trauner M et al. (2005) Molecular regulation of hepatobiliary transport systems: Clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 39 (Suppl 2): S111-S124
31. Ring A and Stremmel W (2000) The hepatic microvascular responses to sepsis. Semin Thromb Hemost 26: 589-594
32. Hirata K et al. (2001) Sepsis and cholestasis: Basic findings in the sinusoid and bile canaliculus. J Hepatobiliary Pancreat Surg 8: 20-26
33. Bateman RM et al. (2003) Bench-to-bedside review: Microvascular dysfunction in sepsis - hemodynamics, oxygen transport, and nitric oxide. Crit Care 7: 359-373
34. Sherlock S (1987) The syndrome of disappearing intrahepatic bile ducts. Lancet 2: 493-496
35. Trauner M (2003) When bile ducts say NO: The good, the bad, and the ugly. Gastroenterology 124: 847-851
36. Trauner M et al. (1997) Nitric oxide donors stimulate bile flow and glutathione disulfide excretion independent of guanosine 3′,5′-cyclic monophosphate in the isolated perfused rat liver. Hepatology 25: 263-269
37. Myers NC et al. (1996) cGMP stimulates bile acid-independent bile formation and biliary bicarbonate excretion. Am J Physiol 270 (Pt 1): G418-G424
38. Dufour JF et al. (1995) Nitric oxide blocks bile canalicular contraction by inhibiting inositol trisphosphate-dependent calcium mobilization. Gastroenterology 108: 841-849
39. Burgstahler AD and Nathanson MH (1995) NO modulates the apicolateral cytoskeleton of isolated hepatocytes by a PKC-dependent, cGMP-independent mechanism. Am J Physiol 269 (Pt 1): G789-G799
40. Spirli C et al. (2003) Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124: 737-753
41. Denson LA et al. (2000) Interleukin-1β suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J Biol Chem 275: 8835-8843
42. Karpen SJ et al. (1996) Multiple factors regulate the rat liver basolateral sodium-dependent bile acid co-transporter gene promoter. J Biol Chem 271: 15211-15221
43. Trauner M et al. (1998) Endotoxin down-regulates rat hepatic Ntcp gene expression by decreased activity of critical transcription factors. J Clin Invest 101: 2092-2100
44. Zollner G et al. (2002) Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 282: G184-G191
45. Geier A et al. (2005) Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol 289: G831-G841
46. Lund M et al. (1999) Effects of LPS on transport of indocyanine green and alanine uptake in perfused rat liver. Am J Physiol 277 (Pt 1): G91-G100
47. Cherrington NJ et al. (2004) Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 32: 734-741
48. Zollner G et al. (2001) Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33: 633-646
49. Geier A et al. (2003) Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38: 345-354
50. Lee JM and Boyer JL (2000) Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 20: 373-384
51. Zollner G et al. (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38: 717-727
52. Lee JM et al. (2000) Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 118: 163-172
53. Trauner M et al. (1997) The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113: 255-264
54. Elferink MG et al. (2004) LPS-induced downregulation of MRP2 and BSEP in human liver is due to a post-transcriptional process. Am J Physiol Gastrointest Liver Physiol 287: G1008-G1016
55. Vos TA et al. (1998) Up-regulation of the multidrug resistance genes Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28: 1637-1644
56. Jansen PL and Muller M (1999) Early events in sepsis-associated cholestasis. Gastroenterology 116: 486-488
57. Haussinger D et al. (2000) Short-term regulation of canalicular transport. Semin Liver Dis 20: 307-321
58. Kubitz R et al. (1999) Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 116: 401-410
59. Kuhlkamp T et al. (2005) Degradation of the sodium taurocholate cotransporting polypeptide (NTCP) by the ubiquitin-proteasome system. Biol Chem 386: 1065-1074
60. Han X et al. (2004) Increased iNOS activity is essential for hepatic epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Gastrointest Liver Physiol 286: G126-G136
61. De Maio A et al. (2000) Interruption of hepatic gap junctional communication in the rat during inflammation induced by bacterial lipopolysaccharide. Shock 14: 53-59
62. Gonzalez HE et al. (2002) Regulation of hepatic connexins in cholestasis: Possible involvement of Kupffer cells and inflammatory mediators. Am J Physiol Gastrointest Liver Physiol 282: G991-G1001
63. Spirli C et al. (2001) Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 121: 156-169
64. Scheppach W et al. (2001) Sclerosing cholangitis and liver cirrhosis after extrabiliary infections: Report on three cases. Crit Care Med 29: 438-441
65. Trauner M and Boyer JL (2004) Cholestatic syndromes. Curr Opin Gastroenterol 20: 220-230
66. Fickert P et al. (2002) Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123: 1238-1251
67. Quale JM et al. (1988) Clinical significance and pathogenesis of hyperbilirubinemia associated with Staphylococcus aureus septicemia. Am J Med 85: 615-618
68. Lefkowitch JH (1982) Bile ductular cholestasis: An ominous histopathologic sign related to sepsis and "cholangitis lenta". Hum Pathol 13: 19-24
69. Gossard AA et al. (2005) Secondary sclerosing cholangitis: A comparison to primary sclerosing cholangitis. Am J Gastroenterol 100: 1330-1333
70. Strassburg CP (2003) Gastrointestinal disorders of the critically ill. Shock liver. Best Pract Res Clin Gastroenterol 17: 369-381
71. Seeto RK et al. (2000) Ischemic hepatitis: Clinical presentation and pathogenesis. Am J Med 109: 109-113
72. Johnson RD et al. (1995) Extreme serum elevations of aspartate aminotransferase. Am J Gastroenterol 90: 1244-1245
73. Henrion J et al. (2003) Hypoxic hepatitis: Clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 82: 392-406
74. Gibson PR and Dudley FJ (1984) Ischemic hepatitis: Clinical features, diagnosis and prognosis. Aust NZ J Med 14: 822-825
75. Rivers E et al. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368-1377
76. Annane D et al. (2005) Septic shock. Lancet 365: 63-78
77. Bochud PY et al. (2004) Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Crit Care Med 32 (Suppl): S495-S512
78. Bode KA et al. (2002) Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol 64: 151-158
79. Dietrich CG et al. (2003) ABC of oral bioavailability: Transporters as gatekeepers in the gut. Gut 52: 1788-1795
80. Paumgartner G and Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology 36: 525-531
81. Paumgartner G and Beuers U (2004) Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 8: 67-81
82. Beuers U (2006) Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3: 318-328
83. Fickert P et al. (2001) Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121: 170-183
84. Zollner G et al. (2003) Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 39: 480-488
85. Marschall HU et al. (2005) Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485
86. Trauner M and Graziadei IW (1999) Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13: 979-996
87. Keh D and Sprung CL (2004) Use of corticosteroid therapy in patients with sepsis and septic shock: An evidence-based review. Crit Care Med 32 (Suppl): S527-S533
88. Annane D et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862-871
89. Sen S et al. (2005) Emerging indications for albumin dialysis. Am J Gastroenterol 100: 468-475